Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 3/20 | 0.49 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.42 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.42 |
| ▸ | ITGAL | P20701 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 4/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL515169 | 1.00 | ECE1 (0.49) | ECE1ITGB2ICAM1ITGALCA2 | |
| SCHEMBL160995 | 1.00 | ECE1 (0.49) | ECE1ITGB2ICAM1ITGALCA2 | |
| N-Methyl-D-Aspartic Acid (Nmda) SCHEMBL22186670 | 0.94 | ECE1 (0.45) | ECE1ITGB2ICAM1ITGALCA2 | |
| N-Methyl-D-Aspartic Acid (Nmda) SCHEMBL22186671 | 0.94 | ECE1 (0.45) | ECE1ITGB2ICAM1ITGALCA2 | |
| SCHEMBL21381486 | 0.85 | ECE1 (0.45) | ECE1ITGB2ICAM1ITGALCA2 | |
| 1-Aminocyclopropane Carboxylic Acid SCHEMBL15741903 | 0.84 | ECE1 (0.39) | ECE1ITGB2ICAM1ITGALCA2 | |
| SCHEMBL24915343 | 0.83 | ECE1 (0.44) | ECE1ITGB2ICAM1ITGALCA2 | |
| SCHEMBL992852 | 0.83 | ECE1 (0.44) | ECE1ITGB2ICAM1ITGALCA2 | |
| SCHEMBL992850 | 0.83 | ECE1 (0.44) | ECE1ITGB2ICAM1ITGALCA2 | |
| SCHEMBL15866495 | 0.81 | ECE1 (0.37) | ECE1ITGB2ICAM1ITGALCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1555 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240301023-A1 | PEPTIDES AND USES THEREOF | PreveCeutical Medical Inc. (CA) | 2024-09-12 | — | — | US | claimed |
| EP-4175970-A1 | PEPTIDES AND USES THEREOF | Preveceutical Medical Inc. (CA) | 2023-05-10 | — | — | EP | claimed |
| WO-2022000043-A1 | PEPTIDES AND USES THEREOF | PreveCeutical Medical Inc. (CA) | 2022-01-06 | — | — | WO | claimed |
| WO-2019179985-A1 | INHIBITORS OF MINT AND USES THEREOF | UNIVERSITY OF COPENHAGEN (DK) | 2019-09-26 | — | — | WO | claimed |
| US-20090215895-A1 | Therapeutic and carrier molecules | PEPLIN BIOLIPIDS PTY LTD (AU) | 2009-08-27 | — | — | US | claimed |
| US-20090202597-A1 | Ache-Nmda Combination Wafer | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2009-08-13 | — | — | US | claimed |
| EP-1718602-A4 | THERAPEUTIC AND CARRIER MOLECULES | PEPLIN BIOLIPIDS PTY LTD (AU) | 2007-12-12 | — | — | EP | claimed |
| US-7256172-B1 | Method of treatment and agents useful for same | THE UNIVERSITY OF MELBOURNE (AU) | 2007-08-14 | — | — | US | claimed |
| EP-1718602-A1 | THERAPEUTIC AND CARRIER MOLECULES | Peplin Biolipids Pty Ltd. (AU) | 2006-11-08 | — | — | EP | claimed |
| WO-2005073164-A1 | THERAPEUTIC AND CARRIER MOLECULES | PEPLIN BIOLIPIDS PTY LTD (AU) | 2005-08-11 | — | — | WO | claimed |
| CN-1159325-A | Co-therapy for Parkinson's syndrome | PFIZER (US) | 1997-09-17 | — | — | CN | claimed |
| JP-11180972-A | — | — | None | — | — | JP | disclosed |
| US-20260140060-A1 | COLORIMETRIC DETECTION OF A VIRAL INFECTION | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2026-05-21 | — | — | US | disclosed |
| US-20260124281-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF PARATHYROID HORMONE | ENTERA BIO LTD. (IL) | 2026-05-07 | — | — | US | disclosed |
| WO-2026085582-A1 | PROTEIN CAGES | THE UNIVERSITY OF SYDNEY (AU) | 2026-04-30 | — | — | WO | disclosed |
| WO-1994028014-A2 | PEPTIDE INHIBITORS OF UROKINASE RECEPTOR ACTIVITY | CHIRON CORPORATION (US) | 1994-12-08 | — | — | WO | disclosed |
| WO-1994011388-A1 | SUPPORT FOR THE SYNTHESIS OF MODULAR POLYMERS | CHIRON MIMOTOPES PTY. LTD. (AU) | 1994-05-26 | — | — | WO | disclosed |
| WO-1994003483-A1 | ENDOTHELIN RECEPTOR-BINDING COMPOUNDS | CHIRON CORPORATION (US) | 1994-02-17 | — | — | WO | disclosed |
| US-5112863-A | N-Acyl Amino Acid Derivative | NIPPON OIL & FATS CO., LTD. (JP) | 1992-05-12 | — | — | US | disclosed |
| EP-0432039-A2 | Antipsychotic drug comprising an acylaminoacid | NIPPON OILS & FATS CO., LTD. (JP) | 1991-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215895-A1 | Therapeutic and carrier molecules | PHKG1, PHKG2, DGKB | ECE1 862/4885ITGB2 3755/4885ICAM1 505/4885 |
| US-20240301023-A1 | PEPTIDES AND USES THEREOF | OPRL1, OPRK1, OPRM1 | ECE1 1170/4885ITGB2 4216/4885ICAM1 3233/4885 |
| US-20260124281-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF PARATHYROID HORMONE | PTH1R, FGF23, PTMS | ECE1 2241/4885ITGB2 661/4885ICAM1 1198/4885 |
| US-20260140060-A1 | COLORIMETRIC DETECTION OF A VIRAL INFECTION | CTSL, CPA4, ACE2 | ECE1 438/4885ITGB2 4461/4885ICAM1 2153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.